JP2013536193A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536193A5 JP2013536193A5 JP2013524226A JP2013524226A JP2013536193A5 JP 2013536193 A5 JP2013536193 A5 JP 2013536193A5 JP 2013524226 A JP2013524226 A JP 2013524226A JP 2013524226 A JP2013524226 A JP 2013524226A JP 2013536193 A5 JP2013536193 A5 JP 2013536193A5
- Authority
- JP
- Japan
- Prior art keywords
- membered
- nitrogen
- sulfur
- oxygen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 352
- 229910052757 nitrogen Inorganic materials 0.000 claims description 281
- 229910052760 oxygen Inorganic materials 0.000 claims description 262
- 229910052717 sulfur Inorganic materials 0.000 claims description 262
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 251
- 239000001301 oxygen Chemical group 0.000 claims description 251
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 250
- 239000011593 sulfur Chemical group 0.000 claims description 249
- 125000005842 heteroatom Chemical group 0.000 claims description 248
- 150000001875 compounds Chemical class 0.000 claims description 175
- 125000001931 aliphatic group Chemical group 0.000 claims description 163
- 229910052739 hydrogen Inorganic materials 0.000 claims description 161
- 239000001257 hydrogen Substances 0.000 claims description 161
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 146
- 125000000623 heterocyclic group Chemical group 0.000 claims description 130
- 125000002723 alicyclic group Chemical group 0.000 claims description 128
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 121
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 110
- 125000000217 alkyl group Chemical group 0.000 claims description 92
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 81
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 48
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000002947 alkylene group Chemical group 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 28
- 125000004429 atom Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000001188 haloalkyl group Chemical group 0.000 claims description 19
- 125000001624 naphthyl group Chemical group 0.000 claims description 18
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 17
- -1 heterocyclyl nitrogen Chemical group 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 150000002780 morpholines Chemical class 0.000 claims description 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 5
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 2
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004354 sulfur functional group Chemical group 0.000 claims 1
- 0 CCc(c(NC(C)=O)c1)ccc1-c1cc(C(c(cc2)ccc2Cl)N(C)C)c(*(N)NC=N)[s]1 Chemical compound CCc(c(NC(C)=O)c1)ccc1-c1cc(C(c(cc2)ccc2Cl)N(C)C)c(*(N)NC=N)[s]1 0.000 description 6
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 5
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- IVGYAVLIMBGBES-UHFFFAOYSA-N C(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)n1)c1cc(cccc2)c2cc1 Chemical compound C(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)n1)c1cc(cccc2)c2cc1 IVGYAVLIMBGBES-UHFFFAOYSA-N 0.000 description 1
- GFJUWVQZDGYBKW-XEHXNRTPSA-O CC(/C(/c1nc(Cc(cc2)ccc2Cl)c(C(NC=[NH2+])=N)[s]1)=C1\NC=CC(CN(CCN)Cc2ccccc2)=C1)=N Chemical compound CC(/C(/c1nc(Cc(cc2)ccc2Cl)c(C(NC=[NH2+])=N)[s]1)=C1\NC=CC(CN(CCN)Cc2ccccc2)=C1)=N GFJUWVQZDGYBKW-XEHXNRTPSA-O 0.000 description 1
- URQRCWQPJRQUSR-RHUIJKDASA-N CC(C)(C)OC(NCCNCC(C=CN1)=C/C1=C(/C(C)=N)\c1nc(Cc(cc2)ccc2Cl)c(C(NC=N)=N)[s]1)=O Chemical compound CC(C)(C)OC(NCCNCC(C=CN1)=C/C1=C(/C(C)=N)\c1nc(Cc(cc2)ccc2Cl)c(C(NC=N)=N)[s]1)=O URQRCWQPJRQUSR-RHUIJKDASA-N 0.000 description 1
- ZVBVUPVLCMPBBU-UHFFFAOYSA-N CC(Nc1cc(-c2cc(C(c3ccccc3)N3C(CO)CCC3)c(-c3nnc[nH]3)[s]2)ccn1)=O Chemical compound CC(Nc1cc(-c2cc(C(c3ccccc3)N3C(CO)CCC3)c(-c3nnc[nH]3)[s]2)ccn1)=O ZVBVUPVLCMPBBU-UHFFFAOYSA-N 0.000 description 1
- YWXYNDGEGQIUFL-UHFFFAOYSA-N CC(Nc1nccc(-c2nc(Cc3ccc(C)cc3)c(-c3ncc[nH]3)[s]2)c1)=O Chemical compound CC(Nc1nccc(-c2nc(Cc3ccc(C)cc3)c(-c3ncc[nH]3)[s]2)c1)=O YWXYNDGEGQIUFL-UHFFFAOYSA-N 0.000 description 1
- LWNADROKZGHQNJ-UHFFFAOYSA-N CCOC(c1c(Cc2ccccc2)[s]c(-c2c(N)nc(Nc(c(C3CCN(Cc4c(C(O)=O)nc(-c5ccncc5)[s]4)CC3)c3)ccc3S(N)(=O)=O)[s]2)n1)=O Chemical compound CCOC(c1c(Cc2ccccc2)[s]c(-c2c(N)nc(Nc(c(C3CCN(Cc4c(C(O)=O)nc(-c5ccncc5)[s]4)CC3)c3)ccc3S(N)(=O)=O)[s]2)n1)=O LWNADROKZGHQNJ-UHFFFAOYSA-N 0.000 description 1
- YGLXNHDCECOXJF-UHFFFAOYSA-N CCOC(c1c(Nc(cccc2)c2N)nc(-c2ccncc2)[s]1)=O Chemical compound CCOC(c1c(Nc(cccc2)c2N)nc(-c2ccncc2)[s]1)=O YGLXNHDCECOXJF-UHFFFAOYSA-N 0.000 description 1
- URNMXNVOLWQODN-UHFFFAOYSA-N COC(c1c(-c2ccccc2)[s]c(N2CCOCC2)c1C(OC)=O)=O Chemical compound COC(c1c(-c2ccccc2)[s]c(N2CCOCC2)c1C(OC)=O)=O URNMXNVOLWQODN-UHFFFAOYSA-N 0.000 description 1
- LIRLOKQRIUYQTA-UHFFFAOYSA-N COC(c1c(C(c2ccccc2)=O)[s]c(N2CCOCC2)c1C(OC)=O)=O Chemical compound COC(c1c(C(c2ccccc2)=O)[s]c(N2CCOCC2)c1C(OC)=O)=O LIRLOKQRIUYQTA-UHFFFAOYSA-N 0.000 description 1
- KMHLYFVZYMSJIL-UHFFFAOYSA-N COC(c1c(N2CCOCC2)[s]c(N2CCOCC2)c1C(OC)=O)=O Chemical compound COC(c1c(N2CCOCC2)[s]c(N2CCOCC2)c1C(OC)=O)=O KMHLYFVZYMSJIL-UHFFFAOYSA-N 0.000 description 1
- LILNOIHLTWXJAQ-UHFFFAOYSA-N COc1nccc(-c2cc(C(c(cc3)ccc3Cl)O)c(-c3cnc[nH]3)[s]2)c1 Chemical compound COc1nccc(-c2cc(C(c(cc3)ccc3Cl)O)c(-c3cnc[nH]3)[s]2)c1 LILNOIHLTWXJAQ-UHFFFAOYSA-N 0.000 description 1
- FZJTWKIMGASGOS-UHFFFAOYSA-O C[NH2+]C(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c(cc1)ccc1Cl Chemical compound C[NH2+]C(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c(cc1)ccc1Cl FZJTWKIMGASGOS-UHFFFAOYSA-O 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- BTZWPJBSNYNOPU-UHFFFAOYSA-N Cc1cc(-c2nc(Cc(cc3)ccc3Cl)c(-c3n[nH]cn3)[s]2)ccn1 Chemical compound Cc1cc(-c2nc(Cc(cc3)ccc3Cl)c(-c3n[nH]cn3)[s]2)ccn1 BTZWPJBSNYNOPU-UHFFFAOYSA-N 0.000 description 1
- GCEBGUNLHLTBFG-UHFFFAOYSA-N Cc1cc(Nc2nc(-c3nc(C(N)=O)c(NC4CCCCC4)[s]3)ccn2)cc(C)c1 Chemical compound Cc1cc(Nc2nc(-c3nc(C(N)=O)c(NC4CCCCC4)[s]3)ccn2)cc(C)c1 GCEBGUNLHLTBFG-UHFFFAOYSA-N 0.000 description 1
- YLSWDXMFMDFPGV-UHFFFAOYSA-O Cc1n[n](ccc(CNCc(ccc(O)c2)c2OC)c2)c2c1-c1nc(Cc(cc2)ccc2Cl)c(C(NC=[NH2+])=N)[s]1 Chemical compound Cc1n[n](ccc(CNCc(ccc(O)c2)c2OC)c2)c2c1-c1nc(Cc(cc2)ccc2Cl)c(C(NC=[NH2+])=N)[s]1 YLSWDXMFMDFPGV-UHFFFAOYSA-O 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- WPFVNRJLEFHHAW-UHFFFAOYSA-N Clc1ccc(CC2N=C(c3ccncc3)SC2c2ncc[nH]2)cc1 Chemical compound Clc1ccc(CC2N=C(c3ccncc3)SC2c2ncc[nH]2)cc1 WPFVNRJLEFHHAW-UHFFFAOYSA-N 0.000 description 1
- ZKPGMRDTKXYXHG-UHFFFAOYSA-N Clc1ccc(Cc2c(-c3ccc[nH]3)[s]c(-c3ccncc3)n2)cc1 Chemical compound Clc1ccc(Cc2c(-c3ccc[nH]3)[s]c(-c3ccncc3)n2)cc1 ZKPGMRDTKXYXHG-UHFFFAOYSA-N 0.000 description 1
- PAOHVEJPICCIAB-UHFFFAOYSA-N Clc1ccc(Cc2c(-c3nnc[nH]3)[s]c(-c3ccncc3)c2)cc1 Chemical compound Clc1ccc(Cc2c(-c3nnc[nH]3)[s]c(-c3ccncc3)c2)cc1 PAOHVEJPICCIAB-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- AHPXUBQFGUTJLI-UHFFFAOYSA-N N#Cc1nccc(-c2cc(C(c(cc3)ccc3Cl)O)c(-c3nnc[nH]3)[s]2)c1 Chemical compound N#Cc1nccc(-c2cc(C(c(cc3)ccc3Cl)O)c(-c3nnc[nH]3)[s]2)c1 AHPXUBQFGUTJLI-UHFFFAOYSA-N 0.000 description 1
- IIFNGLLRZTYGCX-UHFFFAOYSA-O N=C(c1c(C(c(cc2)ccc2Cl)O)cc(-c2c(cc[nH]3)c3ncc2)[s]1)NC=[NH2+] Chemical compound N=C(c1c(C(c(cc2)ccc2Cl)O)cc(-c2c(cc[nH]3)c3ncc2)[s]1)NC=[NH2+] IIFNGLLRZTYGCX-UHFFFAOYSA-O 0.000 description 1
- ZALDHYUQHCTHPS-UHFFFAOYSA-O N=C(c1c(Cc2cc(cccc3)c3cc2)c(C#N)c(-c2ccnnc2)[s]1)NC=[NH2+] Chemical compound N=C(c1c(Cc2cc(cccc3)c3cc2)c(C#N)c(-c2ccnnc2)[s]1)NC=[NH2+] ZALDHYUQHCTHPS-UHFFFAOYSA-O 0.000 description 1
- ULDHYBNXNYNKCJ-UHFFFAOYSA-N NCc1c[nH]c(-c2c(Cc(cc3)ccc3Cl)nc(-c3ccncc3)[s]2)n1 Chemical compound NCc1c[nH]c(-c2c(Cc(cc3)ccc3Cl)nc(-c3ccncc3)[s]2)n1 ULDHYBNXNYNKCJ-UHFFFAOYSA-N 0.000 description 1
- KLTZOMYINRBVCW-UHFFFAOYSA-N Nc1cc(-c([s]c(C(NC=N)=N)c2Cc(cc3)ccc3Cl)c2C#N)ccn1 Chemical compound Nc1cc(-c([s]c(C(NC=N)=N)c2Cc(cc3)ccc3Cl)c2C#N)ccn1 KLTZOMYINRBVCW-UHFFFAOYSA-N 0.000 description 1
- ISUZQHYCFMNEGS-UHFFFAOYSA-O Nc1nccc(C2=CC(C(c(cc3)ccc3Cl)O)(C3C(NC=[NH2+])=N)C3S2)n1 Chemical compound Nc1nccc(C2=CC(C(c(cc3)ccc3Cl)O)(C3C(NC=[NH2+])=N)C3S2)n1 ISUZQHYCFMNEGS-UHFFFAOYSA-O 0.000 description 1
- JSSGIIFOUSFCDO-UHFFFAOYSA-N OC(C1C=C(c2ccncc2F)SC1c1nnc[nH]1)c(cc1)ccc1Cl Chemical compound OC(C1C=C(c2ccncc2F)SC1c1nnc[nH]1)c(cc1)ccc1Cl JSSGIIFOUSFCDO-UHFFFAOYSA-N 0.000 description 1
- YTGXXZMASDWKAY-UHFFFAOYSA-N OC(c1c(-c2cnc[nH]2)[s]c(-c2cc(F)ncc2)c1)c(cc1)ccc1Cl Chemical compound OC(c1c(-c2cnc[nH]2)[s]c(-c2cc(F)ncc2)c1)c(cc1)ccc1Cl YTGXXZMASDWKAY-UHFFFAOYSA-N 0.000 description 1
- CBWZWWMMVPPGRO-UHFFFAOYSA-N OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c([o]1)ccc1Br Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c([o]1)ccc1Br CBWZWWMMVPPGRO-UHFFFAOYSA-N 0.000 description 1
- BUVBAPRVUDBPLD-UHFFFAOYSA-O OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c(cc1)ccc1[OH2+] Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c(cc1)ccc1[OH2+] BUVBAPRVUDBPLD-UHFFFAOYSA-O 0.000 description 1
- BMNDMUBCQCBGNL-UHFFFAOYSA-N OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cc2cccnc2cc1 Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cc2cccnc2cc1 BMNDMUBCQCBGNL-UHFFFAOYSA-N 0.000 description 1
- OJXDUFVUISZJCY-UHFFFAOYSA-N OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1ccc2OCOc2c1 Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1ccc2OCOc2c1 OJXDUFVUISZJCY-UHFFFAOYSA-N 0.000 description 1
- XGPIERWYBSTYCL-UHFFFAOYSA-N OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cccc(-c2ccncc2)c1 Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cccc(-c2ccncc2)c1 XGPIERWYBSTYCL-UHFFFAOYSA-N 0.000 description 1
- XDCRSTPHEYQEKE-UHFFFAOYSA-N OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cccc2c1cccc2 Chemical compound OC(c1c(-c2nnc[nH]2)[s]c(-c2ccncc2)c1)c1cccc2c1cccc2 XDCRSTPHEYQEKE-UHFFFAOYSA-N 0.000 description 1
- JNZRJPVGCNEKBP-UHFFFAOYSA-N OC(c1c(CN2CCCC2)[s]c(-c2ccncc2)n1)=O Chemical compound OC(c1c(CN2CCCC2)[s]c(-c2ccncc2)n1)=O JNZRJPVGCNEKBP-UHFFFAOYSA-N 0.000 description 1
- IPOKDAVOOQGESP-UHFFFAOYSA-N OC(c1c(CN2CCNCC2)[s]c(-c2ccncc2)n1)=O Chemical compound OC(c1c(CN2CCNCC2)[s]c(-c2ccncc2)n1)=O IPOKDAVOOQGESP-UHFFFAOYSA-N 0.000 description 1
- FNBPVVQRHCDXRJ-UHFFFAOYSA-N OC(c1c(CN2CCOCC2)[s]c(-c2ccncc2)n1)=O Chemical compound OC(c1c(CN2CCOCC2)[s]c(-c2ccncc2)n1)=O FNBPVVQRHCDXRJ-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37259410P | 2010-08-11 | 2010-08-11 | |
| US61/372,594 | 2010-08-11 | ||
| US201161438375P | 2011-02-01 | 2011-02-01 | |
| US61/438,375 | 2011-02-01 | ||
| PCT/US2011/047407 WO2012021696A1 (en) | 2010-08-11 | 2011-08-11 | Heteroaryls and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013536193A JP2013536193A (ja) | 2013-09-19 |
| JP2013536193A5 true JP2013536193A5 (https=) | 2014-09-25 |
Family
ID=45567940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524226A Pending JP2013536193A (ja) | 2010-08-11 | 2011-08-11 | ヘテロアリール類およびその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US8796268B2 (https=) |
| EP (1) | EP2603214A4 (https=) |
| JP (1) | JP2013536193A (https=) |
| KR (1) | KR20130098334A (https=) |
| CN (1) | CN103153300A (https=) |
| AR (1) | AR082665A1 (https=) |
| AU (1) | AU2011289377A1 (https=) |
| BR (1) | BR112013003358A2 (https=) |
| CA (1) | CA2807971A1 (https=) |
| CL (1) | CL2013000417A1 (https=) |
| CO (1) | CO6690755A2 (https=) |
| CR (1) | CR20130084A (https=) |
| DO (1) | DOP2013000034A (https=) |
| EA (1) | EA201390214A1 (https=) |
| EC (1) | ECSP13012485A (https=) |
| MA (1) | MA34797B1 (https=) |
| MX (1) | MX2013001660A (https=) |
| NZ (1) | NZ607087A (https=) |
| PE (1) | PE20131304A1 (https=) |
| PH (1) | PH12013500274A1 (https=) |
| SG (2) | SG10201506238SA (https=) |
| TW (1) | TW201217365A (https=) |
| UY (1) | UY33554A (https=) |
| WO (1) | WO2012021696A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| WO2010090716A1 (en) | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| TW201217365A (en) | 2010-08-11 | 2012-05-01 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TW201307309A (zh) | 2010-10-13 | 2013-02-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| WO2013010946A2 (en) | 2011-07-15 | 2013-01-24 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests i |
| EP2855489B1 (en) | 2012-04-26 | 2017-01-04 | Bristol-Myers Squibb Company | Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| SI2841437T1 (sl) | 2012-04-26 | 2017-09-29 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| SG11201406759YA (en) | 2012-04-26 | 2014-11-27 | Bristol Myers Squibb Co | Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| UA117359C2 (uk) | 2012-11-14 | 2018-07-25 | Тейдзін Фарма Лімітед | Похідне піридину |
| US20150368236A1 (en) | 2012-12-27 | 2015-12-24 | Basf Se | 2-(pyridin-3-yl)-5-hetaryl-thiazole compounds carrying an imine or imine-derived substituent for combating invertebrate pests |
| WO2015108861A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| CN109810071B (zh) * | 2019-03-28 | 2023-04-21 | 中国科学院成都生物研究所 | 一种miRNA生物合成抑制剂 |
| CN109970703A (zh) * | 2019-05-08 | 2019-07-05 | 玉林师范学院 | 1,3-杂环取代芳香酮的制备方法及应用 |
| CN118496197A (zh) | 2019-12-20 | 2024-08-16 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
| CN116390922B (zh) * | 2020-10-21 | 2025-07-18 | 珠海联邦制药股份有限公司 | 硒杂环类化合物及其应用 |
| WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
| CN119504592B (zh) * | 2024-11-19 | 2025-07-29 | 深圳智微通科技有限公司 | 3-氨基-5-(4-苯氧基苯基)-4-氰基-1h-吡唑的合成方法 |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL242505A (https=) | 1958-08-20 | |||
| US3852293A (en) | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
| US3821384A (en) | 1972-10-06 | 1974-06-28 | Uniroyal Inc | Pharmaceutical compositions containing a4-aryl-2-(3-pyridyl)thiazole and methods of using same |
| DE3021590A1 (de) | 1980-06-09 | 1981-12-17 | Hoechst Ag, 6000 Frankfurt | 4-halogen-5-(halogenmethyl-phenyl)-oxazol-derivate, ein verfahren zu ihrer herstellung und sie enthaltenden strahlungsempfindliche massen |
| DD275870A1 (de) | 1988-09-27 | 1990-02-07 | Univ Leipzig | Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen |
| PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6268308B1 (en) | 1996-08-27 | 2001-07-31 | Syngenta Crop Protection, Inc. | Herbicidal S-substituted 1,2,4,6-thiatriazines |
| JPH1087490A (ja) | 1996-09-10 | 1998-04-07 | Sagami Chem Res Center | インターロイキン６生産抑制剤、骨吸収抑制剤、抗骨粗鬆症剤、及びチアゾール化合物 |
| PT853083E (pt) * | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| ES2167882T3 (es) | 1997-04-24 | 2002-05-16 | Dow Agrosciences Llc | 3-(fenil sustituido)-5-(tienil o furil)-1,2,4-triazoles pesticidas. |
| CA2336848A1 (en) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| DE19858192A1 (de) | 1998-12-17 | 2000-06-21 | Aventis Cropscience Gmbh | 4-Trifluormethyl-3-oxazolylpyridine, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel |
| CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
| JP2003520233A (ja) | 2000-01-18 | 2003-07-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | ジャイレースインヒビターおよびそれらの使用 |
| AU2002338642A1 (en) | 2001-04-13 | 2002-10-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| US7074801B1 (en) | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| US7405235B2 (en) | 2001-05-04 | 2008-07-29 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| ATE325608T1 (de) | 2001-08-13 | 2006-06-15 | Janssen Pharmaceutica Nv | 2,4,5-trisubstituted thiazolyl derivative und deren antiinflammatorische wirkung |
| US7375105B2 (en) | 2001-09-05 | 2008-05-20 | Smithkline Beecham P.L.C. | Pyridine substituted furan derivatives as Raf kinase inhibitors |
| US20040198773A1 (en) | 2001-09-26 | 2004-10-07 | Barry Hart | Substituted 3-pyridyl oxazoles as c17,20 lyase inhibitors |
| EP1432706A2 (en) | 2001-09-26 | 2004-06-30 | Bayer Pharmaceuticals Corporation | 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| AU2002359376B2 (en) | 2001-11-08 | 2008-01-10 | Elan Pharmaceuticals, Inc. | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| BR0313160A (pt) | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
| AU2003265395A1 (en) | 2002-08-14 | 2004-03-03 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| WO2004016741A2 (en) | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use |
| JP2006522125A (ja) * | 2003-03-25 | 2006-09-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチアゾール |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| US6984652B2 (en) | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| GB0324653D0 (en) * | 2003-10-22 | 2003-11-26 | Syngenta Participations Ag | Fungicides |
| EP1718297A4 (en) * | 2004-01-09 | 2009-09-02 | Smithkline Beecham Corp | NEW CHEMICAL COMPOUNDS |
| JP2007519753A (ja) | 2004-01-30 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2005095386A1 (en) | 2004-03-30 | 2005-10-13 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| EP1742627A4 (en) | 2004-05-06 | 2009-08-26 | Plexxikon Inc | PDE4B HEMMER AND ITS USE |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| CA2589827A1 (en) | 2004-12-21 | 2006-06-29 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| MX2007008781A (es) | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
| GB0503962D0 (en) | 2005-02-25 | 2005-04-06 | Kudos Pharm Ltd | Compounds |
| CN1834095B (zh) | 2005-03-18 | 2011-04-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
| EP1869049B1 (en) | 2005-03-21 | 2009-03-04 | Eli Lilly And Company | Imidazopyridazine compounds |
| GB0508471D0 (en) | 2005-04-26 | 2005-06-01 | Celltech R&D Ltd | Therapeutic agents |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| DE102005000046A1 (de) | 2005-04-28 | 2006-11-02 | Voith Patent Gmbh | Maschine zur Herstellung einer Faserstoffbahn |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| JP5222561B2 (ja) | 2005-10-07 | 2013-06-26 | キッセイ薬品工業株式会社 | 含窒素芳香族複素環化合物およびそれを含有する医薬組成物 |
| JP2007197324A (ja) | 2006-01-23 | 2007-08-09 | Toray Ind Inc | ２，４，５−置換−１，３−アゾール誘導体 |
| CA2637933C (en) | 2006-01-24 | 2013-03-12 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
| US7504513B2 (en) | 2006-02-27 | 2009-03-17 | Hoffman-La Roche Inc. | Thiazolyl-benzimidazoles |
| BRPI0709680B8 (pt) | 2006-03-27 | 2021-05-25 | Nerviano Medical Sciences Srl | derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase |
| WO2007129161A2 (en) | 2006-04-26 | 2007-11-15 | F. Hoffmann-La Roche Ag | Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor |
| JP2009535386A (ja) | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | チアゾール誘導体および抗腫瘍剤としてのその使用 |
| WO2007139816A2 (en) | 2006-05-23 | 2007-12-06 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| WO2007138110A2 (en) | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
| AU2007275221A1 (en) | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| US20100143499A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| BRPI0715051A2 (pt) | 2006-08-14 | 2015-05-19 | Schering Corp | Processo e intermediários para a síntese de derivados de 2-(quinolin-5il)-4,5 dissubstituído-azol |
| AU2007287428B2 (en) | 2006-08-24 | 2011-08-11 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
| WO2008024980A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrrole, thiophene, furan, imidazole, oxazole, and thiazole derivatives |
| JP5184536B2 (ja) | 2006-09-20 | 2013-04-17 | イーライ リリー アンド カンパニー | チオフェンピラゾロピリミジン化合物 |
| RU2469034C2 (ru) | 2006-12-04 | 2012-12-10 | Астразенека Аб | Химические соединения |
| WO2008083070A1 (en) | 2006-12-29 | 2008-07-10 | Neurogen Corporation | Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties |
| GB0701426D0 (en) | 2007-01-25 | 2007-03-07 | Univ Sheffield | Compounds and their use |
| JP5461197B2 (ja) | 2007-02-02 | 2014-04-02 | ベイラー カレッジ オブ メディスン | 代謝障害を処置するための組成物および方法 |
| US8420690B2 (en) | 2007-02-07 | 2013-04-16 | Glaxosmithkline Llc | Inhibitors of Akt activity |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| WO2008157273A1 (en) | 2007-06-14 | 2008-12-24 | Smithkline Beecham Corporation | Chemical compounds |
| JP5478488B2 (ja) * | 2007-06-20 | 2014-04-23 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｊａｎｕｓキナーゼの阻害剤 |
| WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
| US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
| US8067613B2 (en) | 2007-07-16 | 2011-11-29 | Abbott Laboratories | Benzimidazole poly(ADP ribose)polymerase inhibitors |
| JP2010540429A (ja) | 2007-09-24 | 2010-12-24 | アクテリオン ファーマシューティカルズ リミテッド | オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類 |
| CA2704711C (en) | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| US9029411B2 (en) | 2008-01-25 | 2015-05-12 | Millennium Pharmaceuticals, Inc. | Thiophenes and uses thereof |
| TW200940537A (en) | 2008-02-26 | 2009-10-01 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
| MX2010010659A (es) | 2008-03-31 | 2010-10-26 | Genentech Inc | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. |
| GB0805818D0 (en) | 2008-03-31 | 2008-04-30 | Ucb Pharma Sa | Therapeutic agents |
| ES2491522T3 (es) | 2008-06-19 | 2014-09-08 | Millennium Pharmaceuticals, Inc. | Derivados de tiofeno o tiazol y su uso como inhibidores de PI3K |
| EP2303852A4 (en) | 2008-06-26 | 2011-12-28 | Glaxosmithkline Llc | ACTIVITY INHIBITORS AKT |
| GB0812309D0 (en) | 2008-07-03 | 2008-08-13 | Ucb Pharma Sa | Therapeutic agents |
| TWI404025B (zh) * | 2008-07-08 | 2013-08-01 | Innolux Corp | 液晶面板驅動方法及液晶顯示器 |
| US8420695B2 (en) | 2008-07-09 | 2013-04-16 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| AU2009279874B2 (en) | 2008-08-04 | 2015-02-12 | Merck Sharp & Dohme Corp. | Oxazole derivatives useful as inhibitors of FAAH |
| AU2009314544C1 (en) | 2008-11-11 | 2015-11-12 | Xcovery Holding Company Llc | PI3K/mTOR kinase inhibitors |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| WO2010080873A1 (en) | 2009-01-08 | 2010-07-15 | Glaxo Group Limited | Oxazoles as modulators of chemokine receptors |
| US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2010090716A1 (en) * | 2009-01-30 | 2010-08-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and their use as pi3k inhibitors |
| US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
| EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| US20110021531A1 (en) | 2009-07-27 | 2011-01-27 | Chobanian Harry | Oxazole derivatives useful as inhibitors of faah |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| SG183304A1 (en) * | 2010-02-17 | 2012-09-27 | Takeda Pharmaceutical | Heterocyclic compound |
| TW201217365A (en) | 2010-08-11 | 2012-05-01 | Millennium Pharm Inc | Heteroaryls and uses thereof |
| US8859768B2 (en) | 2010-08-11 | 2014-10-14 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| TW201307309A (zh) | 2010-10-13 | 2013-02-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| TW201332989A (zh) | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
-
2011
- 2011-08-11 TW TW100128796A patent/TW201217365A/zh unknown
- 2011-08-11 SG SG10201506238SA patent/SG10201506238SA/en unknown
- 2011-08-11 AU AU2011289377A patent/AU2011289377A1/en not_active Abandoned
- 2011-08-11 US US13/207,753 patent/US8796268B2/en active Active
- 2011-08-11 CA CA2807971A patent/CA2807971A1/en not_active Abandoned
- 2011-08-11 MA MA35714A patent/MA34797B1/fr unknown
- 2011-08-11 EP EP11817031.5A patent/EP2603214A4/en not_active Withdrawn
- 2011-08-11 PE PE2013000258A patent/PE20131304A1/es not_active Application Discontinuation
- 2011-08-11 EA EA201390214A patent/EA201390214A1/ru unknown
- 2011-08-11 AR ARP110102929A patent/AR082665A1/es unknown
- 2011-08-11 SG SG2013009964A patent/SG187795A1/en unknown
- 2011-08-11 MX MX2013001660A patent/MX2013001660A/es not_active Application Discontinuation
- 2011-08-11 UY UY0001033554A patent/UY33554A/es not_active Application Discontinuation
- 2011-08-11 CN CN2011800492087A patent/CN103153300A/zh active Pending
- 2011-08-11 BR BR112013003358A patent/BR112013003358A2/pt not_active IP Right Cessation
- 2011-08-11 WO PCT/US2011/047407 patent/WO2012021696A1/en not_active Ceased
- 2011-08-11 NZ NZ607087A patent/NZ607087A/en not_active IP Right Cessation
- 2011-08-11 JP JP2013524226A patent/JP2013536193A/ja active Pending
- 2011-08-11 PH PH1/2013/500274A patent/PH12013500274A1/en unknown
- 2011-08-11 US US13/207,696 patent/US8796271B2/en active Active
- 2011-08-11 KR KR1020137006232A patent/KR20130098334A/ko not_active Withdrawn
-
2013
- 2013-02-11 DO DO2013000034A patent/DOP2013000034A/es unknown
- 2013-02-11 CL CL2013000417A patent/CL2013000417A1/es unknown
- 2013-02-25 CR CR20130084A patent/CR20130084A/es unknown
- 2013-03-07 CO CO13046171A patent/CO6690755A2/es not_active Application Discontinuation
- 2013-03-11 EC ECSP13012485 patent/ECSP13012485A/es unknown
-
2014
- 2014-07-29 US US14/445,376 patent/US20150175563A1/en not_active Abandoned
- 2014-07-29 US US14/445,373 patent/US20150175593A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536193A5 (https=) | ||
| JP7624700B2 (ja) | 癌を治療するためのｉｒｓ／ｓｔａｔ３二重修飾因子と抗癌剤の組み合わせ | |
| JP2017503813A5 (https=) | ||
| JP6843930B2 (ja) | ニトロカテコールの投与計画 | |
| JP6508544B2 (ja) | 腫瘍を治療するための薬用組成物 | |
| TWI332943B (en) | Taxol enhancer compounds | |
| JP2011510080A5 (https=) | ||
| JP5547067B2 (ja) | 治療組成物およびその使用 | |
| JP6021805B2 (ja) | 腫瘍治療剤 | |
| JP2014521653A5 (https=) | ||
| US8377971B2 (en) | Non-flushing niacin analogues, and methods of use thereof | |
| US8063046B2 (en) | Benzamide derivative | |
| JP2019517487A5 (https=) | ||
| JP2015503504A5 (https=) | ||
| JP2015511629A5 (https=) | ||
| CA2427184A1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| KR20150085053A (ko) | 헤테로사이클릭 글루타미나아제 억제제 | |
| JP2015503505A5 (https=) | ||
| JP2016515110A5 (https=) | ||
| CN1511036B (zh) | 包含信号转导抑制剂和埃坡霉素衍生物的联合形式 | |
| CN111836801A (zh) | 用于抑制tnik的化合物及其医疗用途 | |
| JP2014504648A5 (https=) | ||
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| JP2017515857A5 (https=) | ||
| WO2002045750A1 (en) | Combination drugs |